2,532 reports of this reaction
21.1% of all BUPIVACAINE HYDROCHLORIDE reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for BUPIVACAINE HYDROCHLORIDE, manufactured by Hospira, Inc.. There are 2,532 FDA adverse event reports linking BUPIVACAINE HYDROCHLORIDE to DRUG INEFFECTIVE. This represents approximately 21.1% of all 12,011 adverse event reports for this drug.
Patients taking BUPIVACAINE HYDROCHLORIDE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a frequently reported adverse event for BUPIVACAINE HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to drug ineffective, the following adverse reactions have been reported for BUPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 2,532 FDA reports for BUPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 21.1% of all adverse event reports for BUPIVACAINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking BUPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.